Vmbook Online ordering

Biotechnology

Versartis, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery and development of novel therapeutics for the treatment of human growth hormone (hGH) deficiencies. The company's lead product candidate is VS-859, a long-acting recombinant human growth hormone (rhGH) therapy for the treatment of growth hormone deficiency (GHD) in children and adults.

The company's stock, which trades on the NASDAQ stock exchange under the ticker symbol "VSAR," has had a volatile history. The stock price peaked at around $35 per share in early 2015, but has since declined significantly, and is currently trading around $1.50 per share.

In terms of financials, Versartis reported a net loss of $51.3 million for the full year 2020, compared to a net loss of $67.9 million for the full year 2019. The company's revenue for 2020 was $2.1 million, compared to $0.4 million in 2019. The company's research and development expenses for 2020 were $45.3 million, compared to $51.6 million in 2019. As of December 31, 2020, Versartis had cash, cash equivalents and marketable securities of $72.6 million.

It's important to note that Versartis is still in the development stage and has not yet brought a product to market. The company's future success will depend on the outcome of its clinical trials and its ability to secure regulatory approval for VS-859. The company is also highly dependent on the continued support of its existing investors and its ability to secure additional financing.

As with any investment, it's important for potential investors to thoroughly research the company and its financials, and to consider seeking the advice of a financial advisor before making any investment decisions.